论文部分内容阅读
多发性骨髓瘤是一种常见的血液系统恶性肿瘤,经治疗后仍然有很多患者复发,严重威胁人类的健康。癌/睾丸抗原(C/T)抗原是只表达于睾丸和癌细胞的一类抗原,由于睾丸细胞缺少MHCⅠ类分子,不会受到特异性CTL的攻击,但C/T抗原本身具有一定的免疫原性,可以激活机体产生特异性的CTL应答,因此其被认为是目前肿瘤免疫治疗的理想靶分子之一。C/T抗原从1991年被首次报道以来就倍受关注,在此,本文主要综述了C/T抗原在骨髓瘤细胞中的表达及其在多发性骨髓瘤免疫治疗中的价值和前景。
Multiple myeloma is a common hematological malignancy, after treatment there are still many patients relapse, a serious threat to human health. Cancer / testis antigen (C / T) antigen is only expressed in testis and cancer cells of a class of antigens, as testicular cells lack MHC class I molecules will not be attacked by specific CTL, but the C / T antigen itself has a certain immunity Which can activate the body to produce specific CTL response, so it is considered as one of the ideal target of tumor immunotherapy. Since C / T antigen was first reported in 1991, much attention has been paid to C / T antigen expression in myeloma cells and its value and prospect in multiple myeloma immunotherapy.